A novel synergistic effect of iron depletion on antiangiogenic cancer therapy

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2705-2713

  Ohara, Toshiaki ^a   Noma, Kazuhiro ^a   Urano, Shinichi ^a   Watanabe, Shinichiro ^a   Nishitani, Seishi ^a   Tomono, Yasuko ^b   Kimura, Fumiaki ^c   Kagawa, Shunsuke ^a   Shirakawa, Yasuhiro ^a   Fujiwara, Toshiyoshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Okayama   (Japan)

^c Tamano City Hospital   (Japan)

Author keywords

angiogenesis; bevacizumab; chelator; iron

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEFERASIROX; HEMOGLOBIN; IRON CHELATING AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL DENSITY; CELL HYPOXIA; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON BLOOD LEVEL; IRON DEPLETION; IRON RESTRICTION; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OXYGEN SUPPLY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IRON; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875591847     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27943     Document Type: Article

References (39)

1. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
2. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-13.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
4. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-12.
5. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-19.
6. Richmond HG,. Induction of sarcoma in the rat by iron-dextran complex. Br Med J 1959; 1: 947-9.
7. Okada S, Hamazaki S, Toyokuni S, et al. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989; 60: 708-11.
8. Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 830-6.
9. Hann HW, Stahlhut MW, Blumberg BS,. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 1988; 48: 4168-70.
10. Becker A, Stadler P, Lavey RS, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000; 46: 459-66.
11. Vaupel P, Mayer A, Briest S, et al. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003; 63: 7634-7.
12. Shirakawa Y, Naomoto Y, Kimura M, et al. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia. Clin Cancer Res 2000; 6: 541-50.
13. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-74.
14. Schmeding M, Rademacher S, Boas-Knoop S, et al. rHuEPo reduces ischemia-reperfusion injury and improves survival after transplantation of fatty livers in rats. Transplantation 2010; 89: 161-8.
15. Fei J, Hong A, Dobbins TA, et al. Prognostic significance of vascular endothelial growth factor in squamous cell carcinomas of the tonsil in relation to human papillomavirus status and epidermal growth factor receptor. Ann Surg Oncol 2009; 16: 2908-17.
16. Myoung H, Hong SD, Kim YY, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001; 163: 191-200.
17. Hashimoto Y, Watanabe Y, Shirakiya Y, et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci. 2008; 99: 385-90.
18. Ohara T, Takaoka M, Toyooka S, et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci 2011; 102: 1344-9.
19. Kohgo Y, Niitsu Y, Kondo H, et al. Serum transferrin receptor as a new index of erythropoiesis. Blood 1987; 70: 1955-8.
20. Ke Q, Costa M,. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70: 1469-80.
21. Schicher N, Paulitschke V, Swoboda A, et al. Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009; 15: 3495-3502.
22. Argov M, Kashi R, Peer D, et al. Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen. Cancer Lett 2009; 274: 118-25.
23. Shima DT, Deutsch U, D'Amore PA,. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett 1995; 370: 203-8.
24. Guminski AD, Harnett PR, deFazio A,. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 2002; 3: 312-8.
25. Chang A,. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3-10.
26. Tappenden P, Jones R, Paisley S, et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43: 2487-94.
27. Montero AJ, Avancha K, Gluck S, et al. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 2012; 132: 747-51.
28. Ohyashiki JH, Kobayashi C, Hamamura R, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009; 100: 970-77.
29. Lescoat G, Chantrel-Groussard K, Pasdeloup N, et al. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 2007; 40: 755-67.
30. Hoffman, RM,. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17: 343-59.
31. Hoffman, RM,. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5: 796-806.
32. Hoffman RM, Yang M,. Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc 2006; 1: 928-35.
33. Amoh Y, Yang M, Li L, et al. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005; 65: 5352-7.
34. Amoh Y, Li L, Tsuji K, et al. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine. J Surg Res 2006; 132: 164-9.
35. Shih T, Lindley C,. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779-1802.
36. Wheatley-Price P, Shepherd FA,. Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008; 3: 1173-84.
37. Jubb AM, Harris AL,. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11: 1172-83.
38. Mancuso A, Sternberg CN,. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice? Crit Rev Oncol Hematol 2005; 55: 67-81.
39. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.